

WHAT IS CLAIMED IS:

1. A compound according to formula I



wherein

Ind is unsubstituted indol-3-yl, indol-3-yl monosubstituted by OH, OA, CN, Hal, COR² or CH₂R², or indol-3-yl polysubstituted by OH, OA, CN, Hal, COR², CH₂R² or combinations thereof;

B
R¹ is benzofuran-5-yl, ~~2,3-dihydrobenzofuran-5-yl, chroman-6-yl,~~ chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which in each case is unsubstituted or monosubstituted by CN, CH₂OH, CH₂OA or COR²;

B
Q is C_mH_{2m};

Z is ^N~~N or CR³~~;

A is alkyl having 1-6 C atoms;

Hal is F, Cl, Br or I;

R² is OH, OA, NH₂, NHA or NA₂;

R³ is H, OH or OA; and

m is 2, 3 or 4; or

a physiologically acceptable salt thereof.

2. A compound according to claim 1, wherein said compound is:

(a) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(2-hydroxymethylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;

30

~~(b) 1-[4-(5-carbamoylindol-3-yl)butyl]-4-hydroxy-4-(2,3-dihydrobenzofuran-5-yl)piperidine or a physiologically acceptable salt thereof;~~

~~(c) 1-[4-(5-carbamoylindol-3-yl)butyl]-4-(2,3-dihydrobenzofuran-5-yl)piperidine or a physiologically acceptable salt thereof;~~

~~(d) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(2,3-dihydrobenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;~~

^b
~~(e)~~ 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-ethoxycarbonylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;^{or}

^c
~~(f)~~ 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or a physiologically acceptable salt thereof;^{or}

~~(g) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine or a physiologically acceptable salt thereof;~~
~~or~~

~~(h) 1-[4-(5-hydroxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine or a physiologically acceptable salt thereof.~~

3. A compound according to claim 1, wherein Ind is unsubstituted indol-3-yl, indol-3-yl monosubstituted by OH, OA, CN, Hal, COR² or CH₂R², or indol-3-yl disubstituted by OH, OA, CN, Hal, COR² or CH₂R².

4. A compound according to claim 1, wherein Ind is indol-3-yl monosubstituted in the 5-position by OH, OA, CN, Hal, COR² or CH₂R².

5. A compound according to claim 1, wherein Ind is indol-3-yl monosubstituted in the 4-, 6- or 7-position by OH, OA, CN, Hal, COR² or CH₂R².

6. A compound according to claim 1, wherein A is methyl or ethyl.

B 7. A compound according to claim 1, wherein R¹ is benzofuran-5-yl, ~~2,3-dihydrobenzofuran-5-yl, chroman-6-yl or~~ chroman-4-on-6-yl which, in each case is unsubstituted or monosubstituted by -CH₂OH, -CONH₂, -CO₂A or -CO₂NHA.

8. A compound according to claim 1, wherein Q is -(CH₂)₄-.

9. A compound according to claim 1, wherein Z is -N-, -C(OH)- or -CH-.

10. A compound according to claim 1, wherein Ind is indol-3-yl substituted in the 5-position by OH or OA.

11. A compound according to claim 1, wherein Ind is indol-3-yl substituted in the 5-position by CONH₂ or CN.

B
a 12. A compound according to claim 1, wherein ~~Z is N and~~ ^{benzofuran-5-yl} R¹ is unsubstituted benzofuran-5-yl or ~~benzo-5-yl~~ substituted by CN, CH₂OH, CH₂OA or COR².

13. A compound according to claim 1, wherein Z is -CH(OH)-.

14. A compound according to claim 1, wherein Z is N and R¹ is 2,3-dihydrobenzofuran-5-yl.

15. A compound according to claim 1, wherein Z is N and R¹ is chroman-6-yl.

B 16. A compound according to claim 1, wherein ~~Z is N and~~ R¹ is chromen-4-on-6-yl.

17. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

¹⁷
~~18.~~ A composition according to claim ¹⁹~~17~~, wherein said compound is present in an amount of 0.2-500 mg.

19. A method of treating tension, depression, psychosis or side effects associated with the treatment of hypertension, comprising administering a compound according to claim 1.

20. A method of treating acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome, undesired puerperal lactation, or cerebral disorders, comprising administering a compound according to claim 1.

21. A method of treating migraines, comprising administering a compound according to claim 1.

22. A method according to claim 21, wherein said compound is administered in a daily dosage of 0.001-0.005 mg/kg of body weight.

add
A'